ADAIR is an investigational new drug product and has not yet been approved by the FDA. All trademarks shown are the property of their respective owners.
Marella has more than 30 years of accomplishments in finance and operations having successfully led multiple M&A, licensing, and fundraising transactions. She currently serves as the Chief Accounting Officer of Centessa Pharmaceuticals plc (Nasdaq: CNTA) and previously served as Head of Finance. Prior to that, Marella was the Chief Financial Officer of Palladio Biosciences, leading their finance operations and capital strategy and execution. Before joining Palladio, Marella served in various capacities at Realm Therapeutics, PLC, (Nasdaq: RLM), including Chief Financial Officer, Chief Operating Officer and Executive Director. In this role, she led accounting and financial reporting operations and helped transition Realm’s focus to drug development following a strategic overhaul. She was also responsible for divesting domestic and international operating businesses and in-licensing and out-licensing assets. Earlier in her career Marella worked for Campbell Soup Company (NYSE: CPB) in finance and operational roles of increasing responsibility and at Ernst & Young, LLP where she earned a C.P.A. Marella also serves on the Board of Essa Pharm (Nasdaq: EPIX) and on the Board of Living Beyond Breast Cancer (lbbc.org). Marella earned a B.S. in Business from Lehigh University, magna cum laude.
Joseph is the President and Chief Executive Officer of Arcturus Therapeutics Ltd. He brings with him an exceptional track record of ushering novel therapeutics to the clinic, including targeted RNA medicines utilizing lipid-mediated delivery technologies. Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto as evidenced by over 40 publications and patents, and several investigational new drug (IND) clinical candidates. Joseph earned a Bachelor's Degree in Chemistry, magna cum laude, from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and Executive Training Certification from MIT Sloan School of Management.
Richard is the Managing Owner and Chief Executive Officer of MEDICE Arzneimittel Pütter GmbH & Co. KG (Medice), a family-owned pharmaceutical company based in Iserlohn, Germany. Medice is the #1 ranked pharmaceutical company in sales of prescription ADHD medications across Europe. Richard has served as Medice’s general manager since 2003, responsible for research & development, medical & regulatory affairs, manufacturing, market access and international marketing & distribution. Richard graduated with a degree in medicine from Technical University, Munich and an internship at Harvard Medical School, Boston. His basic and clinical research on atrial fibrillation for which he obtained his PhD was awarded by the European Society in Cardiology with the Young Investigator Award in Basic Science in 2001. Specializing in cardiac and renal care, Richard pursued his clinical education in internal medicine at Massachusetts General Hospital in Boston (1996-2000), the German Heart Center (2000-2001) and the University Hospital in Muenster (2001). Richard also pursued studies in business administration and economics at University St. Gallen (1992-1996) and Harvard Extension School (1996 -1999), completing his Ph.D. in 2005. Since 2001, Richard has served as an assistant professor at University St. Gallen (Switzerland). Since 2006, Richard has served as a board member and Vice President of the German Pharmaceutical Association with a focus on R&D.
Ms. Karson brings over two decades of experience in various leadership roles in the life sciences and biotechnology industries. Most recently, she served as President and Chief Executive Officer of Proteostasis Therapeutics from 2014-2020 where she led the company through a successful IPO and raised over $300M to advance the cystic fibrosis (CF) pipeline from discovery to successful completion of Phase 2 studies with three novel CFTR modulators delivered as a proprietary combination enabling the first ever personalized medicine registrational study for CF. She also led the strategic merger with Yumanity Therapeutics. From 2007 to 2014, Ms. Karson was President and Chief Executive Officer at Allozyne, Inc., Prior to her time at Allozyne, she served as the Chief Business Officer at BioXell SpA, a spin-off from Roche Pharmaceuticals where she led corporate development and financing activities. Ms. has also held roles of increasing responsibility at Novartis, Warner-Lambert Company, LLC, and Bristol-Myers Squibb. Currently, she serves on the board of Vasomune Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the treatment of acute respiratory distress syndrome and is on the Board of Directors for the Biotechnology Innovation Organization (BIO) on its Emerging Companies Section Board. She obtained her M.B.A. from York University and her B.Sc. from the University of Toronto.
David is a co-founder of Vallon and has over 25 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. He has been directly involved with the commercialization of five medications with annual sales in excess of $1 billion each, including Adderall XR® and Vyvanse®, the two most successful ADHD brands based on annual revenue. Previously, David was the Chief Commercial Officer and interim CEO of Alcobra Ltd., a CNS specialty pharmaceutical company that completed a reverse merger with Arcturus Therapeutics in late 2017. Prior to Alcobra, he worked at Shire Plc for 10 years as Vice President of Commercial Strategy and New Business in the Neuroscience Business Unit, Global General Manager for Vyvanse® and Vice President, ADHD Marketing. Prior to Shire, he worked at Merck & Co. in marketing, sales, market research, and business development. Mr. Baker's therapeutic expertise includes ADHD, autism, osteoporosis, migraine, and hyperlipidemia. Mr. Baker earned a bachelor’s degree in Economics and Computer Science from Duke University, and an MBA in Marketing, from Duke’s Fuqua School of Business.
